Nationwide alert in China for the faulty rabies vaccine

The second largest drug manufacturing company “ Changchun Changsheng Life Sciences” were found guilty for violated national standards including usage of expired fluids and falsified production dates to produce rabies vaccine. Rabies Vaccines manufactured in China was widely exported to countries including India too.

This recent scandal of faulty Rabies Vaccines creating panic and especially in China. After taking a quick action on this, country has started a nationwide campaign to provide health consultation and free inoculation of rabies vaccines.

In India, the Drug Controller General of India also ordered immediately to withdraw rabies vaccines from the market and also banned their imports from Changchun Changsheng Life Sciences.

Healthcare centers, institutions and disease control centers have started providing consultation services for those who received or used rabies vaccines made by the company. 36,482 hospitals and health centers are designated by the China government to provide consultation. No life loss has been reported yet from the patients who injected with the faulty Rabies vaccines.

According to the report, Changchun Changsheng making use of expired fluids and false production dates is in continuity since April 2014 and had violated rules on production management and national drug standards for the vaccines.

China National Health Commission and the State Drug Administration are actively working on the issue and created an inoculation plan for patients who have injected rabies vaccines from the Changchun Changsheng company. And the patients who are getting treated and those whose required course are not yet completed can switch to vaccines from other companies at no charge.

China government also start giving free re-inoculated who have completed their courses less than a year ago and vaccination institutions will provide tracking, observation, and advisory services.

Related Posts

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma said the United States Food and Drug Administration (USFDA) has completed an inspection at its Paithan manufacturing facility in Maharashtra, conducted between 13 April and 21 April 2026.…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Boehringer Ingelheim launches AI centre for pharma research in London

Boehringer Ingelheim launches AI centre for pharma research in London

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March